Zobrazeno 1 - 10
of 201
pro vyhledávání: '"Relapse/refractory"'
Publikováno v:
Journal of Blood Medicine, Vol Volume 15, Pp 407-419 (2024)
Jing Wang,1,* Lei Tian,2,* Weilong Zhang,1,* Shuhan Tang,1 Wei Zhao,1 Yu Guo,1 Chaoling Wu,1 Yuansheng Lin,1 Xiaoyan Ke,1 Hongmei Jing1 1Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191
Externí odkaz:
https://doaj.org/article/0c857ff6997545e5a7c314970eb40843
Autor:
Takayoshi Tachibana, Masatsugu Tanaka, Yuma Noguchi, Yuho Najima, Daichi Sadato, Yuka Harada, Yotaro Tamai, Noriko Doki, Hideaki Nakajima
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
The outcomes of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant to new drugs such as tyrosine kinase inhibitors, inotuzumab ozogamicin (InO) and blinatumomab are dismal. We treated two cases of Ph+ALL resista
Externí odkaz:
https://doaj.org/article/0209de57f1fb4edd864fcf22b274fc1b
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/7abba3e277f54984a9f8b019c24e6f3f
Autor:
Yu-Xin Wang, An Wang, Yong-Feng Su, Jun Wang, Yu-Hang Li, Fei Li, Yu Jing, Lei Xu, Yi-Zhi Wang, Xuan Zheng, Chun-Ji Gao, Liang-Ding Hu, Xiao-Ning Gao, Dai-Hong Liu
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionThe prognosis of relapsed/refractory acute myeloid leukemia (r/rAML) is dismal, and allogeneic hematopoietic stem cell transplant (allo-HSCT) is a potential cure. Combining anti-PD-1, hypomethylating agent (HMA), and CAG (cytarabine, acla
Externí odkaz:
https://doaj.org/article/4d92885038114fa3ad788dcad2eb292d
Publikováno v:
Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 14, Pp 1-15 (2024)
Francesco Malfona, Anna Maria Testi, Sabina Chiaretti, Maria Luisa Moleti Department of Translational and Precision Medicine, ‘Sapienza’ University, Rome, ItalyCorrespondence: Maria Luisa Moleti, Hematology Institute, Via Benevento 6, Rome, 00161
Externí odkaz:
https://doaj.org/article/8386e80c5b23479289a8ad8da7b5ba58
Autor:
Sockel, Katja, Stölzel, Friedrich, Hönl, Franziska, Baldauf, Henning, Röllig, Christoph, Wermke, Martin, Bonin, Malte von, Teipel, Raphael, Link-Rachner, Cornelia, Brandt, Kalina, Kroschinsky, Frank, Hänel, Mathias, Morgner, Anke, Klesse, Christian, Ehninger, Gerhard, Platzbecker, Uwe, Bornhäuser, Martin, Schetelig, Johannes, Moritz Middeke, Jan
Introduction: Allogeneic hematopoietic cell transplantation (HCT) during chemotherapy-induced aplasia may offer long-term survival in acute myeloid leukemia (AML) with otherwise poor prognosis including ELN adverse risk, relapsed or refractory diseas
Externí odkaz:
https://tud.qucosa.de/id/qucosa%3A91946
https://tud.qucosa.de/api/qucosa%3A91946/attachment/ATT-0/
https://tud.qucosa.de/api/qucosa%3A91946/attachment/ATT-0/
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Acute lymphoblastic leukemia (ALL) represents a malignancy involving early-stage differentiated lymphoid cells that invade the bone marrow, blood, and extramedullary sites. First-line treatment spans 2–3 years with induction, consolidation, intensi
Externí odkaz:
https://doaj.org/article/4d411e81bc014f4ca4ea010c3aa4d49c
Autor:
Ping Yang, Qing‐qing Cai, Wei Zhang, Shuo‐zi Liu, Hui Liu, Xiu‐hua Sun, Yu‐jun Dong, Xiu‐bin Xiao, Jing‐wen Wang, Zhen‐ling Li, Wen‐rong Huang, Li‐hong Li, Hui‐zheng Bao, Wei Yang, Ya‐lan Wang, Shu‐ye Wang, Juan He, Xiao‐ling Li, Ai‐chun Liu, Hong‐mei Jing
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13204-13216 (2023)
Abstract Background Mantle cell lymphoma (MCL) is an uncommon heterogeneous subtype of B cell non‐Hodgkin lymphoma, and clinical features in MCL appear regional characteristics. MCL treatment opinions are not uniform between countries or regions wi
Externí odkaz:
https://doaj.org/article/ac2dfccadb9c4155b0735bebbad177b8
Autor:
Alexander Russell-Smith, Louise Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah Webb, Stephanie Dorman, Richa Shah
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 2 (2023)
Aim: To compare all-cause and acute lymphoblastic leukemia (ALL)-related healthcare resource utilization (HCRU) and costs among patients receiving inotuzumab ozogamicin (InO) and blinatumomab (Blina) for ALL in the first relapsed/refractory (R/R) s
Externí odkaz:
https://doaj.org/article/84f6838eb08f40ae935e4e8e7f6ff89e
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Inotuzumab ozogamicin (InO) is an antibody drug conjugate composed of a humanized monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic calicheamicin payload via an acid labile linker. InO has shown significant activity
Externí odkaz:
https://doaj.org/article/44c714fac20948a5b4c501e9e91d53d8